GHK-Cu
Matrix and Epithelial
£28.00per vial
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, first isolated from human plasma. Laboratory work examines it in extracellular matrix remodelling, collagen and glycosaminoglycan synthesis models, and gene-expression modulation, where its copper-binding behaviour is the defining variable.
For laboratory research only. Not for human consumption. No medical claims. This product is not intended to diagnose, treat, cure, or prevent any disease.
This vial is sealed for the protection of health and hygiene. Under regulation 28(1)(e) of the Consumer Contracts (Information, Cancellation and Additional Charges) Regulations 2013, the 14-day right to cancel is lost for this item once that seal is broken. While the seal is intact the right applies in full.
GHK-Cu cannot be listed to research users in Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. Verify local eligibility before ordering.
Listed
- Molecular weight
- 400.9 g/mol
- Sequence
- GHK, complexed with copper(II)
- Presentation
- Pre-mixed liquid, 3ml vial
For laboratory research only. Not for human consumption. No medical claims.
- UK DISPATCH
- TRACKED SHIPPING
- COA PER BATCH
- SECURE PAYMENT
§01Compound Profile
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
HPLC
Purity by chromatography
ANALYSED
MASS SPECTROMETRY
Identity confirmation
ANALYSED
PUBLIC COA
Every batch number resolves to its Certificate of Analysis
DOCUMENTED
§02The Science
Published constants and presentation for GHK-Cu, as catalogued.
Every figure in this list is a published constant or a presentation fact. None of it is an analytical result: the measured figures live on the Certificate of Analysis for the batch.
- Molecular weight
- 400.9 g/mol
- Sequence
- GHK, complexed with copper(II)
- Presentation
- Pre-mixed liquid, 3ml vial
- Batch reference
- GH5612
Molecular weight source: PubChem CID 139035031 (copper tripeptide, the copper(II) complex). The free tripeptide ligand alone is 340.4 g/mol, PubChem CID 73587..
§03Certificate of Analysis
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
| PARAMETER | METHOD | RESULT |
|---|---|---|
| Purity | HPLC | 99.2% |
| Identity | Mass spectrometry | Confirmed |
GH5612 · 2026-07-09
§04Compound details
GHK-Cu is a naturally occurring tripeptide that binds copper(II) with high affinity. The peptide was first isolated from human plasma, where its concentration declines measurably with donor age, and that observation is what put it into the tissue-remodelling research literature. The copper coordination is not incidental to the mechanism, it is the mechanism: the complex acts as a copper carrier, and the metal is required for the enzymatic activity the compound is studied against.
Preclinical investigations examine GHK-Cu in extracellular matrix frameworks, including collagen and decorin synthesis models and the balance between matrix metalloproteinases and their tissue inhibitors. Separate work examines it in gene-expression modulation, where transcriptomic studies report broad shifts in expression profile, and in antioxidant and copper-dependent enzymatic system research. Dermal, follicular, and angiogenesis models are the common experimental contexts.
One distinction matters for anyone reading this page from a cosmetic search: GHK-Cu is widely formulated into finished cosmetic serums, which are regulated in Great Britain under the cosmetic products regime and are a different category of item entirely. This listing is not a cosmetic product. It is a research-grade compound catalogued for laboratory use, and it is neither formulated nor labelled for topical application to a person. No therapeutic, diagnostic, cosmetic or clinical conclusion is drawn from any study referenced above, and none should be inferred.
GHK-Cu is listed as a pre-mixed liquid in a sealed 3ml vial, at 50mg and 100mg. It is not a lyophilised presentation and there is no reconstitution step for the research user to perform. The solution carries the characteristic blue colour of the copper(II) complex.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a batch number that resolves to the public Certificate of Analysis for that batch, reporting the compound, the lot reference, the HPLC result, the mass-spectrometry result, the analysis date, and the laboratory that ran it. The document is published before the batch enters the catalogue.
Research Use Only
GHK-Cu is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about GHK-Cu. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for GHK-Cu relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
GHK-Cu cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
Research Context
GHK-Cu is a naturally occurring tripeptide that binds copper(II) with high affinity. The peptide was first isolated from human plasma, where its concentration declines measurably with donor age, and that observation is what put it into the tissue-remodelling research literature. The copper coordination is not incidental to the mechanism, it is the mechanism: the complex acts as a copper carrier, and the metal is required for the enzymatic activity the compound is studied against.
Preclinical investigations examine GHK-Cu in extracellular matrix frameworks, including collagen and decorin synthesis models and the balance between matrix metalloproteinases and their tissue inhibitors. Separate work examines it in gene-expression modulation, where transcriptomic studies report broad shifts in expression profile, and in antioxidant and copper-dependent enzymatic system research. Dermal, follicular, and angiogenesis models are the common experimental contexts.
One distinction matters for anyone reading this page from a cosmetic search: GHK-Cu is widely formulated into finished cosmetic serums, which are regulated in Great Britain under the cosmetic products regime and are a different category of item entirely. This listing is not a cosmetic product. It is a research-grade compound catalogued for laboratory use, and it is neither formulated nor labelled for topical application to a person. No therapeutic, diagnostic, cosmetic or clinical conclusion is drawn from any study referenced above, and none should be inferred.
Analysis and Documentation
GHK-Cu is listed as a pre-mixed liquid in a sealed 3ml vial, at 50mg and 100mg. It is not a lyophilised presentation and there is no reconstitution step for the research user to perform. The solution carries the characteristic blue colour of the copper(II) complex.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a batch number that resolves to the public Certificate of Analysis for that batch, reporting the compound, the lot reference, the HPLC result, the mass-spectrometry result, the analysis date, and the laboratory that ran it. The document is published before the batch enters the catalogue.
Compliance Notice
Research Use Only
GHK-Cu is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about GHK-Cu. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for GHK-Cu relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
GHK-Cu cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
§05Related compounds
§06Questions
No. GHK-Cu is catalogued strictly for in-vitro laboratory research. It is not for human or veterinary consumption and no medical claims are made.
Extracellular matrix remodelling, collagen and glycosaminoglycan synthesis, and gene-expression modulation in laboratory models. Findings are preclinical.
Glycyl-L-histidyl-L-lysine copper. It is a tripeptide that binds a copper(II) ion, and the complex is what is studied rather than the bare peptide.
No. Cosmetic serums containing GHK-Cu are finished cosmetic products regulated under the Great Britain cosmetic products regime. This listing is a research-grade compound catalogued for laboratory use, not formulated or labelled for application to a person.
Pre-mixed liquid in a sealed 3ml vial, at 50mg and 100mg. It is not a lyophilised powder and needs no preparation before laboratory use. The solution is blue, which is the copper(II) complex.
Every batch has a document.
The Certificate of Analysis for a batch is published when that batch is released. Your batch number resolves to the report.
For laboratory research only. Not for human consumption. No medical claims.
